NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Kiora Pharmaceuticals, Inc. KPRX
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.64
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-51.7%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 12-year series below
Revenue
Net income
Per share
USD -2.64
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-51.7%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-35.7%
Each USD of equity lost 52 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 24.3M
total assets, end of FY2025
Total assetsUSD 24.3M
EquityUSD 16.1M
CashUSD 8.7M
Current ratio5.99×
Equity funds 66% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
−0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
·
·
Net income $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.64
0.87
−24.25
−18.55
−57.12
−1.49
−2.23
−4.57
−0.93
−1.51
−2.70
−9.20
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−51.7
22.6
−142.9
−104.5
−113.3
−83.9
−91.2
−308.5
·
−463.5
·
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.01
0.00
0.00
0.02
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
35 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed